Project Grant HT94252510493
Award Date
8/1/25
Completion Date
7/31/28
Dollars Obligated
$543K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
The federal Project Grant award of $624,000.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The award, with a performance period from September 1, 2025, to August 31, 2027, will fund a comprehensive in vivo phenotyping study of fusion-driven pediatric rhabdomyosarcomas conducted by the...
The Department of the Army Medical Command awarded a $544,250 Project Grant to the University of Washington under the Military Medical Research and Development program (CFDA 12.420) to identify epigenetic-based targets against cancer stem cells in rhabdomyosarcoma. The three-year award beginning August 1, 2022 will support research to investigate medical solutions for battlefield injuries by exploring innovative biomedical research approaches. Specifically, the University of Washington will...
This federal Project Grant award for $1,399,812.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The grant is awarded to the Regents of the University of Minnesota to conduct research on outcomes and late effects in pediatric and adolescent germ cell tumor survivors. This funding will enable...
The federal Project Grant award, valued at $176,000.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports the Sloan-Kettering Institute for Cancer Research in establishing a mouse model of myxoid/round cell liposarcoma with endogenous translocations. This research aims to transform healthcare for military service members, veterans, and the broader public by advancing biomedical research on critical health...
The Department of the Army Medical Command awarded a $1,528,652 Project Grant to the University of Washington under the Military Medical Research and Development program (CFDA 12.420) to enhance the efficacy of precision oncology-based therapy in rhabdomyosarcoma. The three-year award beginning in August 2021 will support the University of Washington's research into investigating medical solutions for rhabdomyosarcoma on the battlefield and transforming health care for service members and the...
The federal Project Grant award of $1,008,313 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. This award supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The award was granted to The Regents of the University of California, San Francisco (UCSF), a prominent academic medical center and research institution, to conduct research on melanoma....
The federal Project Grant award of $1,578,836.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) in developing and exploiting a third-generation prostate cancer dependency map to identify cancer vulnerabilities and treatment targets. The award, which runs from August 1, 2024 to July 31, 2027, will enable the research organization to conduct innovative...
The Defense Health Agency awarded a $682,049 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from August 1, 2023 to July 31, 2026 to leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
The federal Project Grant award of $932,918 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is supporting research at the University of Washington to determine the role of somatic mosaicism in ovarian cancer predisposition. The grant, awarded on September 30, 2024 with an ultimate completion date of September 29, 2028, will enable the University of Washington to conduct innovative scientific studies to improve health outcomes for military...
This Project Grant award of $1,412,000 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports a biorepository and community development project to characterize aggressive urothelial cancer variants. The University of Washington, as the prime awardee, will conduct this research over a period of approximately 4 years, from September 2024 through August 2028. The project aims to expand understanding of aggressive forms of urothelial (bladder)...